MIE2: Optimisation of Mechanical Insufflation:Exsufflation

Sponsor
Guy's and St Thomas' NHS Foundation Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT04163198
Collaborator
Royal Brompton & Harefield NHS Foundation Trust (Other)
30
1
2
27.4
1.1

Study Details

Study Description

Brief Summary

Patients with neuromuscular diseases (NMD) can suffer from a range of respiratory problems due to respiratory muscle weakness. Cough muscle weakness means secretion clearance from the airways can be problematic, a source of infection, and importantly a cause of death, in this patient group. Therefore, these patients are often supported with devices to aid clearance, such as mechanical insufflation-exsufflation (MIE). Although evidence supports the use of these devices, the optimal technique or settings on the device are not clear. Increasingly, higher pressures are used during MIE and recent work has demonstrated that there may be a physiological benefit to this. However, higher pressures increase the risk of causing lung collapse and may cause detriment to blood flow back to the heart, which is important as NMD patients frequently have concurrent heart muscle weakness. Further, recent work has demonstrated that higher pressures can cause closure of the throat, which is counter-productive in secretion clearance.

The overall aim of this study is to investigate methods to manipulate MIE to improve secretion clearance in patients with NMD. The questions it seeks to answer are:

(i) how can we maximally improve lung recruitment during inspiration, whilst maintaining patient comfort and lower pressures (ii) what is the smallest pressure difference required in expiration to achieve an improvement in cough (iii) do these proposed changes to MIE also cause throat closure (iv) what factors do patients believe contribute to their adherence to MIE therapy?

Patients with slowly progressive or stable neuromuscular diseases will be included in the study. Participation will involve two visits to the Lane Fox Respiratory Unit, each lasting approximately four hours. Patients will be recruited from specialist neuromuscular respiratory clinics by their clinical teams.

Condition or Disease Intervention/Treatment Phase
  • Device: Insufflation
  • Device: Exsufflation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Investigating Methods to Improve Secretion Clearance Using Mechanical Insufflation:Exsufflation in Patients With Neuromuscular Disease.
Actual Study Start Date :
Dec 19, 2019
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Apr 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Insufflation optimisation

Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.

Device: Insufflation
Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.

Experimental: Exsufflation optimisation

Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF

Device: Exsufflation
Patients will receive different exsufflation pressures at fixed insufflation pressure.

Outcome Measures

Primary Outcome Measures

  1. Cough peak expiratory flow (cPEF) [2 days]

    Change in cPEF with different modalities of MI-E

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Stable or slowly progressive neuromuscular disease

  • Respiratory muscle weakness (FVC <60%, snip <60%, sleep disordered breathing)

  • Clinical evidence of respiratory secretions or cough peak expiratory flow <270 and history of lower respiratory tract infection

  • Documented clinical stability by supervising clinician

Exclusion Criteria:
  • Rapidly progressive neuromuscular disease (such as motor neuron disease)

  • Decompensated respiratory failure (pH < 7.35)

  • Pregnancy

  • Aged <18

  • Change in ventilator settings in preceding 4 weeks

  • Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol

Contacts and Locations

Locations

Site City State Country Postal Code
1 Guys & St. Thomas' NHS Foundation Trust London United Kingdom SE1 7EH

Sponsors and Collaborators

  • Guy's and St Thomas' NHS Foundation Trust
  • Royal Brompton & Harefield NHS Foundation Trust

Investigators

  • Study Chair: Patrick Murphy, PhD, Guys and St Thomas' NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Guy's and St Thomas' NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT04163198
Other Study ID Numbers:
  • 1.0
First Posted:
Nov 14, 2019
Last Update Posted:
Jun 4, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 4, 2021